NeurAxon To Focus On Migraine With Aura For Potential First-In-Class nNOS Inhibitor
This article was originally published in The Pink Sheet Daily
A Phase II trial of NXN-188 missed the primary endpoint in migraine, but a post hoc analysis showed stronger efficacy in patients with history of aura.
You may also be interested in...
Treximet will hit the U.S. market in mid-May, GSK says.
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.